within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AC11_Tulobuterol;

model Tulobuterol
  extends Pharmacolibrary.Drugs.ATC.R.R03AC11;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R03AC11</td></tr><td>route:</td><td>transdermal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tulobuterol is a long-acting beta2-adrenergic receptor agonist used as a bronchodilator for the treatment of bronchial asthma, chronic bronchitis, and other chronic obstructive pulmonary diseases. It is often administered as a transdermal patch and is approved for use in several countries, including Japan.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a healthy adult population after transdermal administration, as published data are very limited.</p><h4>References</h4><ol><li><p>Kim, JH, et al., &amp; Seo, KW (2016). The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration. <i>Veterinary journal (London, England : 1997)</i> 208 90–92. DOI:<a href=\"https://doi.org/10.1016/j.tvjl.2015.10.012\">10.1016/j.tvjl.2015.10.012</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26639828/\">https://pubmed.ncbi.nlm.nih.gov/26639828</a></p></li><li><p>Takizawa, Y, et al., &amp; Fukai, F (2017). Skin permeability of tulobuterol in two transdermal formulations and their followability. <i>Drug discoveries &amp; therapeutics</i> 11(5) 253–258. DOI:<a href=\"https://doi.org/10.5582/ddt.2017.01050\">10.5582/ddt.2017.01050</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29021505/\">https://pubmed.ncbi.nlm.nih.gov/29021505</a></p></li><li><p>Park, SI, &amp; Kim, BH (2018). Bioequivalence assessment of tulobuterol transdermal delivery system in healthy subjects . <i>International journal of clinical pharmacology and therapeutics</i> 56(8) 381–386. DOI:<a href=\"https://doi.org/10.5414/CP203268\">10.5414/CP203268</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29932416/\">https://pubmed.ncbi.nlm.nih.gov/29932416</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Tulobuterol;
